Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High‐Dose Cancer Therapy

Ng‐Cashin, Judith; Shea, Thomas C.

doi:10.1002/9780470987070.ch45

Cited by 9 publications

(18 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PBSCs have progressively replaced BM as the source of stem cells for autologous transplant. [1][2][3] Current data suggest that greater than 2.0 Â 10 6 CD34 þ cells/kg are needed to assure reliable and sustained hematopoietic recovery after auto-SCT. [4][5][6] Failure to transplant a sufficient number of hematopoietic stem cells can lead to delayed engraftment or graft failure.…”

Section: Introductionmentioning

confidence: 99%

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Fowler

Dunn

Hayes-Lattin

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Fowler

Dunn

Hayes-Lattin

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Following administration of myelosuppressive chemotherapy, a proliferation occurs of both HSCs and progenitor cells in the bone marrow, resulting in some of these cells migrating into the circulation (Ng-Cashin, 2004). The number of HSCs and progenitor cells released into the peripheral blood after chemotherapy can be enhanced by the addition of cytokines.…”

Section: Chemotherapy and Cytokinesmentioning

confidence: 99%

Mobilization of Hematopoietic Stem Cells for Use in Autologous Transplantation

Devine

Tierney²,

Schmit-Pokorny³

et al. 2010

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

Autologous hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic approach for various malignant hematologic and lymphoid diseases. Hematopoietic stem cells (HSCs) may be collected from the blood or the bone marrow. HSCs are capable of self-renewal and give rise to progenitor cells, multipotent cells that differentiate and proliferate into the mature cells of the blood and immune system. HSCs and progenitor cells are released from the bone marrow into the peripheral blood through a process called mobilization. HSCs then are collected from the blood in a process called apheresis and cryopreserved for administration following the high-dose preparative regimen. This article reviews stem cell biology, current mobilization strategies, use of novel mobilization agents, and nursing care of patients during the mobilization phase of autologous HSCT. Understanding the biology and process of HSC mobilization is critical for transplantation nurses to deliver and coordinate care during this complex phase of autologous HSCT.

show abstract

“…Patients had stage IC-IV at initial diagnosis according to the AJCC staging system and had relapsed with nodal and/or visceral metastases. Patients had relapsed or had residual active GCT after a median 1.5 lines (range, 1-4) of therapy and a median of 6.5 cisplatin-based cycles (range, [3][4][5][6][7][8][9][10][11][12][13]. Two patients had received previous local radiotherapy for residual disease.…”

Section: Patients' Characteristicsmentioning

confidence: 99%

“…As it is currently a common practice to perform tandem or multiple sequential cycles of HDC, it is anticipated that collection of large numbers of HSCs from the PB is a prerequisite for the success of this procedure. Moreover, the CD34 + cell dose/kg of patient's body weight infused after HDC has proven to be a major determinant of hematopoietic engraftment, with patients who receive more than 2 Â 10 6 CD34 + cells/kg having consistently rapid and sustained hematopoietic recovery [7]. However, many patients with relapsed/refractory GCTs have been exposed to multiple cycles of intensive myelosuppressive chemotherapy, which compromises the efficacy of HSC mobilization with granulocyte colony-stimulating factor (G-CSF)±chemotherapy [8,9].…”

Section: Introductionmentioning

confidence: 99%

Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors

Kosmas¹,

Athanasopoulos

Dimitriadis³

et al. 2014

Anti-Cancer Drugs

View full text Add to dashboard Cite

An appreciable percentage of patients with relapsed/refractory germ-cell tumors (GCTs), candidates for high-dose chemotherapy (HDC) and autologous hematopoietic cell transplantation (HCT), fail to mobilize adequate hematopoietic stem cells (HSCs) numbers with granulocyte colony-stimulating factor (G-CSF)±salvage chemotherapy. Plerixafor has shown a potential to mobilize adequate CD34+HSCs numbers in this context. Here, we applied plerixafor in combination with G-CSF after salvage chemotherapy in 'poor' mobilizers with relapsed/refractory GCTs for HDC+HCT. Patients with relapsed/refractory GCTs (n=10) received salvage paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy+G-CSF to mobilize adequate HSCs to support HDC, mainly with two courses of high-dose thiotepa-etoposide-carboplatin (TEC). Patients failing to achieve the minimum collection threshold of 2.0×10/kg CD34+ cells, to support at least one cycle of HDC, were administered plerixafor before the anticipated HSC collection during subsequent cycle(s). Overall, seven patients mobilized adequate CD34+ cells (>5.0×10/kg) aiming to support two cycles of HDC. Three patients did not mobilize adequate numbers of CD34+ cells after previous G-CSF plus salvage TIP, and plerixafor was added in subsequent cycle(s). This led to a collection of adequate CD34+ cells, able to support HDC with TEC (1-2 cycles). Hematopoietic engraftment for neutrophils (absolute neutrophil count>500/μl) and platelets (platelet count>20 000/μl) with plerixafor-mobilized HSCs occurred after a median of 9 and 14 days, respectively. Salvage TIP+G-CSF leads to successful HSC mobilization in patients with less heavily pretreated GCTs, whereas the addition of plerixafor to G-CSF+TIP led to mobilization of adequate HSCs that supported autografting after one to two TEC cycles.

show abstract

Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High‐Dose Cancer Therapy

Cited by 9 publications

References 148 publications

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

Mobilization of Hematopoietic Stem Cells for Use in Autologous Transplantation

Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors

Contact Info

Product

Resources

About